

SmartPA Criteria Proposal

Drug/Drug Class:	Non-Oral Contraceptives Fiscal Edit
First Implementation Date:	January 25, 2012
Proposed Date:	December 16, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: To control expenditures by preventing duplication of non-oral contraceptive products

Why Issue Selected: Non-oral contraceptive agents include intrauterine devices (hormone-containing and copper-containing), transdermal patches, long-acting intramuscular injections, vaginal rings, and diaphragm devices. These options of birth control are largely safe and effective, with most products offering the patient the convenience of continuous contraception without requiring the use of a daily oral tablet. More than 10% of women who use birth control now chose a non-oral form. Because of the long-acting nature of these products, MO HealthNet has discovered the need to monitor utilization of these claims to prevent duplication of therapy from the various providers involved in the patient's care.

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Fiscal Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Non-Oral Contraceptives
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Claim is within approved frequency limitations (see Appendix A)

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception code "0683" (Fiscal Edit)
 Rule Type: CE

Default Approval Period

1 year

Appendix A

Brand Name	Generic Name	Frequency Limitation
Annovera Vaginal Ring	Segesterone Acetate/Ethinyl Estradiol	Once every 310 days
Caya Contoured Diaphragm	Diaphragm, Contoured 60mm – 85mm	Once every 310 days
Depo-Provera 104 SubQ	Medroxyprogesterone Acetate Syringe	Once every 71 days
Depo-Provera Syringe	Medroxyprogesterone Acetate Syringe	Once every 71 days
Depo-Provera Vial	Medroxyprogesterone Acetate Vial	Once every 71 days
Diaphragm(s)	Coil/Flat Spring/Arc-Spring	Once every 310 days
Femcap Cervical Cap	Cervical Cap	Once every 310 days
Kyleena IUD System	Levonorgestrel	Once every 1,551 days
Liletta IUD System	Levonorgestrel	Once every 1,861 days
Mirena IUD System	Levonorgestrel	Once every 1,551 days
Nexplanon Implant	Etonogestrel	Once every 930 days
Nuvaring Vaginal Ring	Etonogestrel/Ethinyl Estradiol	Once every 24 days
Paragard T IUD	Copper Intra-Uterine Device	Once every 3,102 days
Phexxi 1.8-1-0.4% vaginal gel	Lactic acid/citric/potassium	2 boxes every 24 days
Skylla IUD System	Levonorgestrel	Once every 930 days
Twirla 120-30 mcg/day patch	Levonorgestrel/Ethinyl Estradiol	Once every 24 days
Xulane Patch	Ethinyl Estradiol/Norelgestromin	Once every 24 days

References

- IPD Analytics. Women's Health: Contraception. Accessed November 17, 2021.

SmartPA Fiscal Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.